Giuliano Costa; Francesco Saia; Thomas Pilgrim; Mohamed Abdel-Wahab; Philippe Garot; Sofia Sammartino; Caterina Gandolfo; Luca Branca; Azeem Latib; Ignacio Amat-Santos; Darren Mylotte; Federico De Marco; Ole De Backer; Luis Nombela Franco; Mariama Akodad; Flavio Luciano Ribichini; Francesco Bedogni; Alessandro Mazzapicchi; Daijiro Tomii; Pietro Laforgia; Stefano Cannata; Claudia Fiorina; Andrea Scotti; Simone Fezzi; Enrico Criscione; Enrico Poletti; Mattia Mazzucca; Mattia Lunardi; Andrea Mainardi; Stefano Andreaggi; Angelo Quagliana; Nicholas Montarello; Breda Hennessey; Matias Mon-Noboa; David Meier; Marianna Adamo; Carmelo Sgroi; Claudia Maria Reddavid; Orazio Strazzieri; Silvia Crescenzia Motta; Valentina Frittitta; Elena Dipietro; Alessandro Comis; Chiara Melfa; Mariachiara Calì; Giulia Laterra; Holger Thiele; John G. Webb; Lars Sondergaard; Corrado Tamburino; Marco Barbanti

doi:10.4244/EIJ-D-23-00720

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

The reference multimedia journal in interventional cardiology

Original Research

DOI: 10.4244/EIJ-D-23-00720

One-year clinical outcomes of transcatheter aortic valve implantation with the latest iteration of self-expanding or balloon expandable devices: insights from the OPERA-TAVI registry

Giuliano Costa¹, MD; Francesco Saia², MD; Thomas Pilgrim³, MD; Mohamed Abdel-Wahab⁴, MD; Philippe Garot⁵, MD; Sofia Sammartino¹, MD; Caterina Gandolfo⁶, MD; Luca Branca⁷, MD; Azeem Latib⁸, MD; Ignacio Amat-Santos⁹, MD; Darren Mylotte¹⁰, MD; Federico De Marco¹¹, MD; Ole De Backer¹², MD; Luis Nombela Franco¹³, MD; Mariama Akodad⁵^,¹⁴, MD, PhD; Flavio Luciano Ribichini¹⁵, MD; Francesco Bedogni¹⁶, MD; Alessandro Mazzapicchi², MD; Daijiro Tomii³, MD; Pietro Laforgia⁵, MD; Stefano Cannata⁶, MD; Claudia Fiorina⁷, MD; Andrea Scotti⁸, MD; Simone Fezzi¹⁰, MD; Enrico Criscione¹⁶, MD; Enrico Poletti¹⁶, MD; Mattia Mazzucca¹⁶, MD; Mattia Lunardi¹⁵, MD; Andrea Mainardi¹⁵, MD; Stefano Andreaggi¹⁵, MD; Angelo Quagliana¹², MD; Nicholas J. Montarello¹², MD; Breda Hennessey¹³, MD; Matias Mon-Noboa¹³, MD; David Meier¹⁴, MD; Marianna Adamo⁷, MD; Carmelo Sgroi¹, MD; Claudia Maria Reddavid¹, MD; Orazio Strazzieri¹, MD; Silvia Crescenzia Motta¹, MD; Valentina Frittitta¹, MD; Elena Dipietro¹, MD; Alessandro Comis¹, MD; Chiara Melfa¹, MD; Mariachiara Calì¹, MD; Giulia Laterra¹⁷, MD; Holger Thiele⁴, MD; John G. Webb¹⁴, MD; Lars Sondergaard¹²^,¹⁸, MD; Corrado Tamburino¹, MD; Marco Barbanti¹⁹, MD

Abstract

Background: Midterm comparative analyses of the latest iterations of the most used Evolut and SAPIEN platforms for transcatheter aortic valve implantation (TAVI) are lacking.

Aims: We aimed to compare 1-year clinical outcomes of TAVI patients receiving Evolut PRO/PRO+ (PRO) or SAPIEN 3 Ultra (ULTRA) devices in current real-world practice.

Methods: Among patients enrolled in the OPERA-TAVI registry, patients with complete 1-year follow-up were considered for the purpose of this analysis. One-to-one propensity score matching was used to compare TAVI patients receiving PRO or ULTRA devices. The primary endpoint was a composite of 1-year all-cause death, disabling stroke and rehospitalisation for heart failure. Five prespecified subgroups of patients were considered according to leaflet and left ventricular outflow tract calcifications, annulus dimensions and angulation, and leaflet morphology.

Results: Among a total of 1,897 patients, 587 matched pairs of patients with similar clinical and anatomical characteristics were compared. The primary composite endpoint did not differ between patients receiving PRO or ULTRA devices (Kaplan-Meier [KM] estimates 14.0% vs 11.9%; log-rank p=0.27). Patients receiving PRO devices had higher rates of 1-year disabling stroke (KM estimates 2.6% vs 0.4%; log-rank p=0.001), predominantly occurring within 30 days after TAVI (1.4% vs 0.0%; p=0.004). Outcomes were consistent across all the prespecified subsets of anatomical scenarios (all p_interaction>0.10).

Conclusions: One-year clinical outcomes of patients undergoing transfemoral TAVI and receiving PRO or ULTRA devices in the current clinical practice were similar, but PRO patients had higher rates of disabling stroke. Outcomes did not differ across the different anatomical subsets of the aortic root.

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com